| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Medicine [D. L. E., H. H., C. S. J.] and Pathology [A. K. B.], University of Arizona, Tucson, Arizona 85721 and Department of Medicine [R. K. W., M. B., H. R., S. K., T. A. B.], University of Chicago, Chicago, Illinois 60637
The present studies were conducted at the Universities of Chicago and Arizona to examine and compare the effects of supplemental dietary ursodeoxycholic acid to cholic acid, a known tumor promoter, and to piroxicam, a known chemopreventive agent, in the azoxymethane (AOM) model of experimental colonic carcinogenesis. Male Fischer 344 rats were utilized in these experiments. All animals were fed a basal diet (AIN-76) supplemented with 0.2% or 0.4% cholic acid, 0.2% or 0.4% ursodeoxycholic acid, 0.2% ursodeoxycholic acid plus 0.2% cholic acid, or 75 ppm piroxicam. Rats were given s.c. injections once a week for 2 weeks with AOM (15 mg/kg body wt/week) or vehicle (saline) after being fed their respective diets for 2 weeks. The rats in each group were then maintained on their respective diets for approximately 28 weeks; after sacrifice, their colons were removed and examined macroscopically and microscopically for the presence of tumors.
The results of these studies demonstrated that none of the control rats fed the various diets injected with AOM-vehicle developed tumors. In groups receiving AOM, the addition of cholic acid (0.4%) caused a significant increase in the incidence of tumors. In contrast, the addition of 0.2% ursodeoxycholic acid did not promote AOM-induced colonic tumors, and when it was added to a promoting dose of cholic acid (0.2%), 0.2% ursodeoxycholic acid prevented enhancement of tumor promotion. At higher doses (0.4%), supplemental dietary ursodeoxycholic acid significantly reduced the incidence of colon tumors and cancers. Moreover, the tumor suppressive effects of 0.4% ursodeoxycholic acid exceeded that of dietary piroxicam. Our results further emphasize the important role of bile salts in modulating colonic tumor development. These studies also demonstrate for the first time that supplemental dietary ursodeoxycholic acid is a chemopreventive agent in the AOM model of experimental colonic carcinogenesis.
1 The study was funded in part by Ciba-Geigy, Inc., the Samuel Freedman Laboratories for Cancer Research, USPHS Grants CA 36745 and CA 41108 awarded by the National Cancer Institute, and USPHS Grant DK 42086 (Digestive Disease Core Research Center).
2 To whom requests for reprints should be addressed, at The University of Chicago, Hospitals and Clinics, MC 4076, 5841 South Maryland Avenue, Chicago, IL 60637.
3 Recipient of a MERIT Award from the National Cancer Institute.
Received 2/18/94. Accepted 7/27/94.
This article has been cited by other articles:
|
|
 |
|
  S. ASCIUTTI, D. CASTELLANI, E. NARDI, O. MORELLI, M. CLEMENTI, F. CHISTOLINI, G. GENTILI, K. D. R. SETCHELL, N. O'CONNELL, R. PELLICCIARI, et al. A New Amino Acid Derivative of Ursodeoxycholate, (N-L-Glutamyl)-UDCA (UDCA-Glu), to Selectively Release UDCA in the Colon Anticancer Res, December 1, 2009; 29(12): 4971 - 4979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Thompson, B. C. Wertheim, D. J. Roe, E. L. Ashbeck, E. T. Jacobs, P. Lance, M. E. Martinez, and D. S. Alberts Gender Modifies the Effect of Ursodeoxycholic Acid in a Randomized Controlled Trial in Colorectal Adenoma Patients Cancer Prevention Research, December 1, 2009; 2(12): 1023 - 1030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Dougherty, D. Cerasi, I. Taylor, M. Kocherginsky, U. Tekin, S. Badal, L. Aluri, A. Sehdev, S. Cerda, R. Mustafi, et al. Epidermal Growth Factor Receptor Is Required for Colonic Tumor Promotion by Dietary Fat in the Azoxymethane/Dextran Sulfate Sodium Model: Roles of Transforming Growth Factor-{alpha} and PTGS2 Clin. Cancer Res., November 15, 2009; 15(22): 6780 - 6789. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Amaral, R. J. S. Viana, R. M. Ramalho, C. J. Steer, and C. M. P. Rodrigues Bile acids: regulation of apoptosis by ursodeoxycholic acid J. Lipid Res., September 1, 2009; 50(9): 1721 - 1734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Castro, J. D. Amaral, S. Sola, B. T. Kren, C. J. Steer, and C. M. P. Rodrigues Differential regulation of cyclin D1 and cell death by bile acids in primary rat hepatocytes Am J Physiol Gastrointest Liver Physiol, July 1, 2007; 293(1): G327 - G334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kohno, R. Suzuki, Y. Yasui, S. Miyamoto, K. Wakabayashi, and T. Tanaka Ursodeoxycholic Acid versus Sulfasalazine in Colitis-Related Colon Carcinogenesis in Mice Clin. Cancer Res., April 15, 2007; 13(8): 2519 - 2525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Khare, C. Holgren, and A. M. Samarel Deoxycholic acid differentially regulates focal adhesion kinase phosphorylation: role of tyrosine phosphatase ShP2 Am J Physiol Gastrointest Liver Physiol, December 1, 2006; 291(6): G1100 - G1112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Jean-Louis, S. Akare, M. A. Ali, E. A. Mash Jr., E. Meuillet, and J. D. Martinez Deoxycholic Acid Induces Intracellular Signaling through Membrane Perturbations J. Biol. Chem., May 26, 2006; 281(21): 14948 - 14960. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Alberts, M. E. Martinez, L. M. Hess, J. G. Einspahr, S. B. Green, A. K. Bhattacharyya, J. Guillen, M. Krutzsch, A. K. Batta, G. Salen, et al. Phase III Trial of Ursodeoxycholic Acid To Prevent Colorectal Adenoma Recurrence J Natl Cancer Inst, June 1, 2005; 97(11): 846 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A.A. Brosens, C. A. Iacobuzio-Donahue, J. J. Keller, S. R. Hustinx, R. Carvalho, F. H. Morsink, L. M. Hylind, G. J. Offerhaus, F. M. Giardiello, and M. Goggins Increased Cyclooxygenase-2 Expression in Duodenal Compared with Colonic Tissues in Familial Adenomatous Polyposis and Relationship to the -765G -> C COX-2 Polymorphism Clin. Cancer Res., June 1, 2005; 11(11): 4090 - 4096. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Tarao, S. Fujiyama, S. Ohkawa, K. Miyakawa, S. Tamai, S. Hirokawa, T. Masaki, and K. Tanaka Ursodiol Use Is Possibly Associated with Lower Incidence of Hepatocellular Carcinoma in Hepatitis C Virus-Associated Liver Cirrhosis Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 164 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Hess, M. F. Krutzsch, J. Guillen, H-H. S. Chow, J. Einspahr, A.K. Batta, G. Salen, M. E. Reid, D. L. Earnest, and D. S. Alberts Results of a Phase I Multiple-Dose Clinical Study of Ursodeoxycholic Acid Cancer Epidemiol. Biomarkers Prev., May 1, 2004; 13(5): 861 - 867. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Im and J. D. Martinez Ursodeoxycholic Acid (UDCA) Can Inhibit Deoxycholic Acid (DCA)-induced Apoptosis via Modulation of EGFR/Raf-1/ERK Signaling in Human Colon Cancer Cells J. Nutr., February 1, 2004; 134(2): 483 - 486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Khare, S. Cerda, R. K. Wali, F. C. von Lintig, M. Tretiakova, L. Joseph, D. Stoiber, G. Cohen, K. Nimmagadda, J. Hart, et al. Ursodeoxycholic Acid Inhibits Ras Mutations, Wild-type Ras Activation, and Cyclooxygenase-2 Expression in Colon Cancer Cancer Res., July 1, 2003; 63(13): 3517 - 3523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.-D. Duan, Y. Cheng, G. Hansen, E. Hertervig, J.-J. Liu, I. Syk, H. Sjostrom, and A. Nilsson Purification, localization, and expression of human intestinal alkaline sphingomyelinase J. Lipid Res., June 1, 2003; 44(6): 1241 - 1250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Wali, S. Khare, M. Tretiakova, G. Cohen, L. Nguyen, J. Hart, J. Wang, M. Wen, A. Ramaswamy, L. Joseph, et al. Ursodeoxycholic Acid and F6-D3 Inhibit Aberrant Crypt Proliferation in the Rat Azoxymethane Model of Colon Cancer: Roles of Cyclin D1 and E-Cadherin Cancer Epidemiol. Biomarkers Prev., December 1, 2002; 11(12): 1653 - 1662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Wali, D. Stoiber, L. Nguyen, J. Hart, M. D. Sitrin, T. Brasitus, and M. Bissonnette Ursodeoxycholic Acid Inhibits the Initiation and Postinitiation Phases of Azoxymethane-induced Colonic Tumor Development Cancer Epidemiol. Biomarkers Prev., November 1, 2002; 11(11): 1316 - 1321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lechner, U. Muller-Ladner, K. Schlottmann, B. Jung, M. McClelland, J. Ruschoff, J. Welsh, J. Scholmerich, and F. Kullmann Bile acids mimic oxidative stress induced upregulation of thioredoxin reductase in colon cancer cell lines Carcinogenesis, August 1, 2002; 23(8): 1281 - 1288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Oyama, G. Shiota, H. Ito, Y. Murawaki, and H. Kawasaki Reduction of hepatocarcinogenesis by ursodeoxycholic acid in rats Carcinogenesis, May 1, 2002; 23(5): 885 - 892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Y. Tung, M. J. Emond, R. C. Haggitt, M. P. Bronner, M. B. Kimmey, K. V. Kowdley, and T. A. Brentnall Ursodiol Use Is Associated with Lower Prevalence of Colonic Neoplasia in Patients with Ulcerative Colitis and Primary Sclerosing Cholangitis Ann Intern Med, January 16, 2001; 134(2): 89 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Gråsten, K. S. Juntunen, K. S. Poutanen, H. K. Gylling, T. A. Miettinen, and H. M. Mykkänen Rye Bread Improves Bowel Function and Decreases the Concentrations of Some Compounds That Are Putative Colon Cancer Risk Markers in Middle-Aged Women and Men J. Nutr., September 1, 2000; 130(9): 2215 - 2221. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. A. Janne and R. J. Mayer Chemoprevention of Colorectal Cancer N. Engl. J. Med., June 29, 2000; 342(26): 1960 - 1968. [Full Text] [PDF]
|
|
|
|
 |
|
 N. N. Izzat, M. E. Deshazer, and D. S. Loose-Mitchell New Molecular Targets for Cholesterol-Lowering Therapy J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 315 - 320. [Abstract] [Full Text]
|
|
|
|
|
|
V. Kozoni, G. Tsioulias, S. Shiff, and B. Rigas The effect of lithocholic acid on proliferation and apoptosis during the early stages of colon carcinogenesis: differential effect on apoptosis in the presence of a colon carcinogen Carcinogenesis, May 1, 2000; 21(5): 999 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Wali, S. Skarosi, J. Hart, Y. Zhang, M.e. Dolan, R. C. Moschel, L. Nguyen, R. Mustafi, T. A. Brasitus, and M. Bissonnette Inhibition of O6-methylguanine-DNA methyltransferase increases azoxymethane-induced colonic tumors in rats Carcinogenesis, December 1, 1999; 20(12): 2355 - 2360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Alberts A Unifying Vision of Cancer Therapy for the 21st Century J. Clin. Oncol., November 1, 1999; 17(90001): 13 - 21. [Full Text] [PDF]
|
|
|
|
|
|
A. K. Batta, G. Salen, K. R. Rapole, M. Batta, P. Batta, D. Alberts, and D. Earnest Highly simplified method for gas-liquid chromatographic quantitation of bile acids and sterols in human stool J. Lipid Res., June 1, 1999; 40(6): 1148 - 1154. [Abstract] [Full Text]
|
|
|
|
 |
|
 M LANGMAN and P BOYLE Chemoprevention of colorectal cancer Gut, October 1, 1998; 43(4): 578 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Batta, G. S. Tint, G. Xu, S. Shefer, and G. Salen Synthesis and intestinal metabolism of ursodeoxycholic acid conjugate with an antiinflammatory agent, 5-aminosalicylic acid J. Lipid Res., August 1, 1998; 39(8): 1641 - 1646. [Abstract] [Full Text]
|
|
|
|
 |
|
 M.B. Thompson Bile Acids in the Assessment of Hepatocellular Function Toxicol Pathol, January 1, 1996; 24(1): 62 - 71. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
